Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines
Identifieur interne : 000040 ( Pmc/Corpus ); précédent : 000039; suivant : 000041Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines
Auteurs : D. Hannani ; C. Locher ; T. Yamazaki ; V. Colin-Minard ; M. Vetizou ; L. Aymeric ; S. Viaud ; D. Sanchez ; M J Smyth ; P. Bruhns ; G. Kroemer ; L. ZitvogelSource :
- Cell Death and Differentiation [ 1350-9047 ] ; 2013.
Abstract
Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4+ and CD8+ T cells producing interferon-
Url:
DOI: 10.1038/cdd.2013.60
PubMed: 23744294
PubMed Central: 3857618
Links to Exploration step
PMC:3857618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines</title>
<author><name sortKey="Hannani, D" sort="Hannani, D" uniqKey="Hannani D" first="D" last="Hannani">D. Hannani</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locher, C" sort="Locher, C" uniqKey="Locher C" first="C" last="Locher">C. Locher</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yamazaki, T" sort="Yamazaki, T" uniqKey="Yamazaki T" first="T" last="Yamazaki">T. Yamazaki</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Colin Minard, V" sort="Colin Minard, V" uniqKey="Colin Minard V" first="V" last="Colin-Minard">V. Colin-Minard</name>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"><institution>Department of Pediatric and Adolescent Oncology</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vetizou, M" sort="Vetizou, M" uniqKey="Vetizou M" first="M" last="Vetizou">M. Vetizou</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Aymeric, L" sort="Aymeric, L" uniqKey="Aymeric L" first="L" last="Aymeric">L. Aymeric</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Viaud, S" sort="Viaud, S" uniqKey="Viaud S" first="S" last="Viaud">S. Viaud</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sanchez, D" sort="Sanchez, D" uniqKey="Sanchez D" first="D" last="Sanchez">D. Sanchez</name>
<affiliation><nlm:aff id="aff5"><institution>Department of Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic</institution>
, Prague,<country>Czech Republic</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation><nlm:aff id="aff6"><institution>Queensland Institute of Medical Research</institution>
, Herston, 4006, Queensland,<country>Australia</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff7"><institution>School of Medicine, The University of Queensland</institution>
, Brisbane, QLD 4072, Queensland,<country>Australia</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bruhns, P" sort="Bruhns, P" uniqKey="Bruhns P" first="P" last="Bruhns">P. Bruhns</name>
<affiliation><nlm:aff id="aff8"><institution>Institut Pasteur, Département d'Immunologie, Laboratoire Anticorps en Thérapie et Pathologie</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff9"><institution>INSERM U760</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kroemer, G" sort="Kroemer, G" uniqKey="Kroemer G" first="G" last="Kroemer">G. Kroemer</name>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff10"><institution>INSERM U848</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff11"><institution>Sorbonne Paris Cité, University of Paris Descartes</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff12"><institution>Equipe 11 labellisée Ligue contre le Cancer, Centre de recherche des Cordeliers</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff13"><institution>Pôle de Biologie, Hôpital Européen Georges Pompidou</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Zitvogel, L" sort="Zitvogel, L" uniqKey="Zitvogel L" first="L" last="Zitvogel">L. Zitvogel</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff14"><institution>Center of clinical Investigations in Biotherapies of Cancer (CICBT)</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23744294</idno>
<idno type="pmc">3857618</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857618</idno>
<idno type="RBID">PMC:3857618</idno>
<idno type="doi">10.1038/cdd.2013.60</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000040</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000040</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines</title>
<author><name sortKey="Hannani, D" sort="Hannani, D" uniqKey="Hannani D" first="D" last="Hannani">D. Hannani</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locher, C" sort="Locher, C" uniqKey="Locher C" first="C" last="Locher">C. Locher</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Yamazaki, T" sort="Yamazaki, T" uniqKey="Yamazaki T" first="T" last="Yamazaki">T. Yamazaki</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Colin Minard, V" sort="Colin Minard, V" uniqKey="Colin Minard V" first="V" last="Colin-Minard">V. Colin-Minard</name>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff4"><institution>Department of Pediatric and Adolescent Oncology</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vetizou, M" sort="Vetizou, M" uniqKey="Vetizou M" first="M" last="Vetizou">M. Vetizou</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Aymeric, L" sort="Aymeric, L" uniqKey="Aymeric L" first="L" last="Aymeric">L. Aymeric</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Viaud, S" sort="Viaud, S" uniqKey="Viaud S" first="S" last="Viaud">S. Viaud</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sanchez, D" sort="Sanchez, D" uniqKey="Sanchez D" first="D" last="Sanchez">D. Sanchez</name>
<affiliation><nlm:aff id="aff5"><institution>Department of Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic</institution>
, Prague,<country>Czech Republic</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation><nlm:aff id="aff6"><institution>Queensland Institute of Medical Research</institution>
, Herston, 4006, Queensland,<country>Australia</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff7"><institution>School of Medicine, The University of Queensland</institution>
, Brisbane, QLD 4072, Queensland,<country>Australia</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bruhns, P" sort="Bruhns, P" uniqKey="Bruhns P" first="P" last="Bruhns">P. Bruhns</name>
<affiliation><nlm:aff id="aff8"><institution>Institut Pasteur, Département d'Immunologie, Laboratoire Anticorps en Thérapie et Pathologie</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff9"><institution>INSERM U760</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kroemer, G" sort="Kroemer, G" uniqKey="Kroemer G" first="G" last="Kroemer">G. Kroemer</name>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff10"><institution>INSERM U848</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff11"><institution>Sorbonne Paris Cité, University of Paris Descartes</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff12"><institution>Equipe 11 labellisée Ligue contre le Cancer, Centre de recherche des Cordeliers</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff13"><institution>Pôle de Biologie, Hôpital Européen Georges Pompidou</institution>
, Paris,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Zitvogel, L" sort="Zitvogel, L" uniqKey="Zitvogel L" first="L" last="Zitvogel">L. Zitvogel</name>
<affiliation><nlm:aff id="aff1"><institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff2"><institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"><institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff14"><institution>Center of clinical Investigations in Biotherapies of Cancer (CICBT)</institution>
, Villejuif,<country>France</country>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Cell Death and Differentiation</title>
<idno type="ISSN">1350-9047</idno>
<idno type="eISSN">1476-5403</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4<sup>+</sup>
and CD8<sup>+</sup>
T cells producing interferon-<italic>γ</italic>
. In many instances, cancer progression is associated with high titers of tumor-specific antibodies, which become detectable in the serum, but whose functional relevance is elusive. Here, we explored the role of humoral immune responses in the anticancer efficacy of anthracyclines. Chemotherapy reduced the number of tumor-infiltrating B cells, and failed to promote humoral responses against immunodominant tumor antigens. Although anthracycline-based anticancer chemotherapies failed in T cell-deficient mice, they successfully reduced the growth of cancers developing in mice lacking B lymphocytes (due to the injection of a B-cell-depleting anti-CD20 antibody), immunoglobulins (Igs) or Ig receptors (Fc receptor) due to genetic manipulations. These results suggest that the humoral arm of antitumor immunity is dispensable for the immune-dependent therapeutic effect of anthracyclines against mouse sarcoma. In addition, we show here that the titers of IgA and IgG antibodies directed against an autoantigen appearing at the cell surface of tumor cells post chemotherapy (calreticulin, CRT) did not significantly increase in patients treated with anthracyclines, and that anti-CRT antibodies had no prognostic or predictive significance. Collectively, our data indicate that humoral anticancer immune responses differ from cellular responses in, thus far, that they do not contribute to the success of anthracycline-mediated anticancer therapies in human breast cancers and mouse sarcomas.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Differ</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell Death Differ</journal-id>
<journal-title-group><journal-title>Cell Death and Differentiation</journal-title>
</journal-title-group>
<issn pub-type="ppub">1350-9047</issn>
<issn pub-type="epub">1476-5403</issn>
<publisher><publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">23744294</article-id>
<article-id pub-id-type="pmc">3857618</article-id>
<article-id pub-id-type="pii">cdd201360</article-id>
<article-id pub-id-type="doi">10.1038/cdd.2013.60</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group><article-title>Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines</article-title>
<alt-title alt-title-type="running">Contribution of B-cell responses after chemotherapy</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Hannani</surname>
<given-names>D</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Locher</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Yamazaki</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Colin-Minard</surname>
<given-names>V</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Vetizou</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Aymeric</surname>
<given-names>L</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Viaud</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sanchez</surname>
<given-names>D</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Smyth</surname>
<given-names>M J</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bruhns</surname>
<given-names>P</given-names>
</name>
<xref ref-type="aff" rid="aff8">8</xref>
<xref ref-type="aff" rid="aff9">9</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kroemer</surname>
<given-names>G</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff10">10</xref>
<xref ref-type="aff" rid="aff11">11</xref>
<xref ref-type="aff" rid="aff12">12</xref>
<xref ref-type="aff" rid="aff13">13</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Zitvogel</surname>
<given-names>L</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="aff" rid="aff14">14</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label>
<institution>INSERM U1015, Equipe labellisée Ligue contre le Cancer</institution>
, Villejuif,<country>France</country>
</aff>
<aff id="aff2"><label>2</label>
<institution>Institut de Cancérologie Gustave Roussy</institution>
, Villejuif,<country>France</country>
</aff>
<aff id="aff3"><label>3</label>
<institution>University of Paris Sud XI</institution>
, Villejuif,<country>France</country>
</aff>
<aff id="aff4"><label>4</label>
<institution>Department of Pediatric and Adolescent Oncology</institution>
, Villejuif,<country>France</country>
</aff>
<aff id="aff5"><label>5</label>
<institution>Department of Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic</institution>
, Prague,<country>Czech Republic</country>
</aff>
<aff id="aff6"><label>6</label>
<institution>Queensland Institute of Medical Research</institution>
, Herston, 4006, Queensland,<country>Australia</country>
</aff>
<aff id="aff7"><label>7</label>
<institution>School of Medicine, The University of Queensland</institution>
, Brisbane, QLD 4072, Queensland,<country>Australia</country>
</aff>
<aff id="aff8"><label>8</label>
<institution>Institut Pasteur, Département d'Immunologie, Laboratoire Anticorps en Thérapie et Pathologie</institution>
, Paris,<country>France</country>
</aff>
<aff id="aff9"><label>9</label>
<institution>INSERM U760</institution>
, Paris,<country>France</country>
</aff>
<aff id="aff10"><label>10</label>
<institution>INSERM U848</institution>
, Villejuif,<country>France</country>
</aff>
<aff id="aff11"><label>11</label>
<institution>Sorbonne Paris Cité, University of Paris Descartes</institution>
, Paris,<country>France</country>
</aff>
<aff id="aff12"><label>12</label>
<institution>Equipe 11 labellisée Ligue contre le Cancer, Centre de recherche des Cordeliers</institution>
, Paris,<country>France</country>
</aff>
<aff id="aff13"><label>13</label>
<institution>Pôle de Biologie, Hôpital Européen Georges Pompidou</institution>
, Paris,<country>France</country>
</aff>
<aff id="aff14"><label>14</label>
<institution>Center of clinical Investigations in Biotherapies of Cancer (CICBT)</institution>
, Villejuif,<country>France</country>
</aff>
</contrib-group>
<author-notes><corresp id="caf1"><label>*</label>
<institution>Department of Immunology, INSERM U805, Institut de Cancérologie Gustave Roussy</institution>
, 39, rue Camille Desmoulins, 114 rue Edouard Vaillant, Villejuif Cedex 94805, <country>France</country>
. Tel: +33 1 42 11 50 41; Fax: +33 1 42 11 60 94; E-mail: <email>zitvogel@igr.fr</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>01</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub"><day>07</day>
<month>06</month>
<year>2013</year>
</pub-date>
<volume>21</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>58</lpage>
<history><date date-type="received"><day>23</day>
<month>01</month>
<year>2013</year>
</date>
<date date-type="rev-recd"><day>24</day>
<month>04</month>
<year>2013</year>
</date>
<date date-type="accepted"><day>26</day>
<month>04</month>
<year>2013</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2014 Macmillan Publishers Limited</copyright-statement>
<copyright-year>2014</copyright-year>
<copyright-holder>Macmillan Publishers Limited</copyright-holder>
</permissions>
<abstract><p>Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4<sup>+</sup>
and CD8<sup>+</sup>
T cells producing interferon-<italic>γ</italic>
. In many instances, cancer progression is associated with high titers of tumor-specific antibodies, which become detectable in the serum, but whose functional relevance is elusive. Here, we explored the role of humoral immune responses in the anticancer efficacy of anthracyclines. Chemotherapy reduced the number of tumor-infiltrating B cells, and failed to promote humoral responses against immunodominant tumor antigens. Although anthracycline-based anticancer chemotherapies failed in T cell-deficient mice, they successfully reduced the growth of cancers developing in mice lacking B lymphocytes (due to the injection of a B-cell-depleting anti-CD20 antibody), immunoglobulins (Igs) or Ig receptors (Fc receptor) due to genetic manipulations. These results suggest that the humoral arm of antitumor immunity is dispensable for the immune-dependent therapeutic effect of anthracyclines against mouse sarcoma. In addition, we show here that the titers of IgA and IgG antibodies directed against an autoantigen appearing at the cell surface of tumor cells post chemotherapy (calreticulin, CRT) did not significantly increase in patients treated with anthracyclines, and that anti-CRT antibodies had no prognostic or predictive significance. Collectively, our data indicate that humoral anticancer immune responses differ from cellular responses in, thus far, that they do not contribute to the success of anthracycline-mediated anticancer therapies in human breast cancers and mouse sarcomas.</p>
</abstract>
<kwd-group><kwd>antibodies</kwd>
<kwd>immunogenic cell death</kwd>
<kwd>chemotherapy</kwd>
<kwd>humoral immunity</kwd>
<kwd>Fc<italic>γ</italic>
R</kwd>
<kwd>cancer</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000040 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000040 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:3857618 |texte= Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23744294" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |